Stockscreener 앱 받기
12.04
3.99%
-0.50
Novocure Ltd 주식(NVCR)의 최신 뉴스
NovoCure Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
NovoCure: Q2 Earnings Snapshot - Norwalk Hour
NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha
Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus
NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Gr - GuruFocus
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure Ltd. Reports Q2 2025 Financial Results - TipRanks
Novocure Beat Revenue Expectations As Patient Numbers Grew - Finimize
How NovoCure Limited stock performs during market volatilityTargeted 200 Percent Gain - Newser
Small U.S. Stocks Decrease; Novocure Takes Biggest Hit - 富途牛牛
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
NovoCure Ltd (NVCR) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Novocure stock hits 52-week low at 14.17 USD - Investing.com Australia
Novocure stock hits 52-week low at 14.17 USD By Investing.com - Investing.com Nigeria
Novocure Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Novocure: Steady Ahead of Key Milestones - The Motley Fool
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
NovoCure Ltd Q2 2025 Earnings: EPS Loss of $0.36 Beats Estimates - GuruFocus
Novocure Ltd earnings beat by $0.02, revenue topped estimates - Investing.com South Africa
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure Reports Second Quarter 2025 Financial Results - Stock Titan
What analysts say about NovoCure Limited stockBreakthrough wealth creation - Autocar Professional
What drives NovoCure Limited stock priceRobust investment performance - jammulinksnews.com
Is NovoCure Limited a good long term investmentUnmatched market gains - jammulinksnews.com
M&T Bank Corp Sells 1,750 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
What makes NovoCure Limited stock price move sharplyFree Stock Market Group - Newser
Why NovoCure Limited stock attracts strong analyst attentionFast Growing Stocks - Newser
NovoCure (NASDAQ:NVCR) shareholders are up 4.2% this past week, but still in the red over the last three years - simplywall.st
Teacher Retirement System of Texas Buys 3,123 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Ltd Stock Price Falls 3.41% Amid Analyst Predictions of 81.88% Upside - AInvest
LADENBURG THALM/SH SH Initiates Coverage on NovoCure (NASDAQ:NVCR) - Defense World
NovoCure stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com South Africa
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
NovoCure stock initiated with Buy rating at Ladenburg Thalmann - Investing.com
NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com Nigeria
New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan
Novocure to Present Final Secondary Endpoint Data from the Phase - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Demystifying NovoCure: Insights From 4 Analyst Reviews - Nasdaq
NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable - simplywall.st
Rhumbline Advisers Has $2.69 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles By Investing.com - Investing.com South Africa
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles - Investing.com India
NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView
1.27%
자본화:
|
볼륨(24시간):